Lavoisier S.A.S.
14 rue de Provigny
94236 Cachan cedex
FRANCE

Heures d'ouverture 08h30-12h30/13h30-17h30
Tél.: +33 (0)1 47 40 67 00
Fax: +33 (0)1 47 40 67 02


Url canonique : www.lavoisier.fr/livre/autre/peroxisome-proliferator-activated-receptors-from-basic-science-to-clinical-applications/fruchart/descriptif_1780980
Url courte ou permalien : www.lavoisier.fr/livre/notice.asp?ouvrage=1780980

Peroxisome Proliferator Activated Receptors: From Basic Science to Clinical Applications, Softcover reprint of the original 1st ed. 2002 Medical Science Symposia Series, Vol. 18

Langue : Anglais
Couverture de l’ouvrage Peroxisome Proliferator Activated Receptors: From Basic Science to Clinical Applications
Peroxisome Proliferator Activated Receptors (PPARs) attract great attention in light of the wide spectrum of genes of biological and medical relevance identified as under their control. As a consequence, our knowledge of the role of these receptors in physiology and pathology continues to grow at a fast pace and PPARs have become an interesting target for the treatment of many pathological conditions, including diabetes and atherosclerosis. This volume provides an authoritative view of the current clinical and scientific developments within this evolving area of study.
1. Peroxisome Proliferator Activated Receptor Alpha Coordinates Intermediary Metabolism During Fasting.- 2. Design, Structure, and Function of Novel PPAR Ligands.- 3. Functions of PPAR Gamma in Macrophages and Atherosclerosis.- 4. PPARs and Atherogenesis: Mediators or Modulators of the Inflammatory Response in the Vessel Wall?.- 5. Role of PPARs in Inflammation, Atherosclerosis, and Thrombosis.- 6. Effects of Thiazolidinediones on Vascular Reactivity and Endothelial Dysfunction.- 7. Activation of Human PPAR Subtypes by Pioglitazone.- 8. PPAR? Mechanism of Action Studies.- 9. The Role of PPAR? in Fatty Acid Metabolism and Hepatocarcinogenesis: Studies with PPAR?-Null Mice.- 10. PPAR?, Lipoprotein Metabolism, Metabolic Disease, and Atherosclerosis.- 11. PPAR? and Atherosclerosis.- 12. Regulation of CD36 by PPAR?: Pro- or Anti-atherogenic?.- 13. Anti-inflammatory Properties of High Density Lipoproteins.- 14. The Low-HDL Syndrome: Epidemiology and Pathophysiology.- 15. Diabetes: A Growing CHD Epidemic.- 16. Influence of PPARs on Muscle Lipid Metabolism and Insulin Resistance.- 17. PPAR? in Adipogenesis and Insulin Resistance.- 18. Pharmacology of a Selective Peroxisome Proliferator-Activated Receptor ? Agonist, GW501516, in Obese Dyslipidemic Primates.- 19. PPAR?: A Regulator of Growth and Differentiation.- 20. Peroxisome Proliferator Activator Receptor Gamma Agonists Inhibit the Development of Atherosclerosis in Low Density Lipoprotein Receptor-Deficient Male Mice.- 21. Are Thiazolidinediones Superior to Standard Therapy in the Treatment of Type 2 Diabetes?.- 22. PPAR? Ligands and Intestinal Inflammation.- 23. Inflammatory Mechanisms in Alzheimer’s Disease: ?-Amyloid-Stimulated Proinflammatory Responses Are Blocked by PPAR? Agonists.

Date de parution :

Ouvrage de 172 p.

15.5x23.5 cm

Disponible chez l'éditeur (délai d'approvisionnement : 15 jours).

Prix indicatif 105,49 €

Ajouter au panier

Date de parution :

Ouvrage de 172 p.

15.5x23.5 cm

Sous réserve de disponibilité chez l'éditeur.

Prix indicatif 105,49 €

Ajouter au panier